Stewart Thomas Cole

Stewart Thomas Cole

Auto-generated profile, based on publicly available information

Stewart Thomas Cole

Ineos Oxford Institute for Antimicrobial Research, University of Oxford, Oxford, UK

Research Focus & Metrics

Academic Career Length

26Years (2001-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
8 May 2009 in Science
Verified
Journal Article
Closed access
PDF file
VMVadim Makarov
Vadim Makarov
GMGiulia Manina
Giulia Manina
KMKatarina Mikusova
Katarina Mikusova
UMUte Möllmann
Ute Möllmann
OROlga Ryabova
Olga Ryabova
SCStewart T. Cole
Stewart T. Cole
Ammunition for the TB Wars: Tuberculosis is a major human disease of global importance resulting from infection with the air-borne pathogen Mycobacterium tuberculosis , which is becoming increasingly resistant to all available drugs. An antituberculosis benzothiazinone compound kills mycobacterium in infected cells and in mice. Makarov et al. (p. 801 ) have identified a sulfur atom and nitro residues important for benzothiazinone's activity and used genetic methods and biochemical analysis to identify its target in blocking arabinogalactan biosynthesis during cell-wall synthesis. The compound affects the same pathway as ethambutol, and thus a benzothiazinone drug has the potential to become an important part of treatment of drug-resistant disease and, possibly, replace the less effective ethambutol in the primary treatment of tuberculosis.

1 May 2014 in Antimicrobial Agents and Chemotherapy
Verified
Journal Article
Open access
PDF file
RHRuben C Hartkoorn
Ruben C Hartkoorn
SUSwapna Uplekar
Swapna Uplekar
SCStewart T. Cole
Stewart T. Cole
The antileprosy drug clofazimine is also of interest for the treatment of multidrug-resistant tuberculosis. To understand possible resistance mechanisms, clofazimine-resistant Mycobacterium tuberculosis mutants were isolated in vitro , and, unexpectedly, found to be cross-resistant to bedaquiline. Mutations in the transcriptional regulator Rv0678, with concomitant upregulation of the multisubstrate efflux pump, MmpL5, accounted for this cross-resistance. Mutation in Rv0678 should therefore be considered a confounding factor for the treatment of tuberculosis with clofazimine or bedaquiline.

1 June 2015 in Cell Host & Microbe
Verified
Journal Article
Closed access
RWRuth Wassermann
Ruth Wassermann
MGMuhammet F. Gulen
Muhammet F. Gulen
Claudia SalaClaudia Sala
Claudia Sala
SPSonia Garcia Perin
Sonia Garcia Perin
YLYe Lou
Ye Lou
AAAndrea Ablasser
Andrea Ablasser

1 November 2009 in Nature Genetics
Verified
Journal Article
Open access
PDF file
MMMarc Monot
Marc Monot
NHNadine Honoré
Nadine Honoré
TGThierry Garnier
Thierry Garnier
NZNora Zidane
Nora Zidane
DSDiana Sherafi
Diana Sherafi
SCStewart T Cole
Stewart T Cole
Stewart Cole and colleagues report the genome sequence and comparative analyses of Brazilian, Indian, North American and Thai strains of Mycobacterium leprae, the etiologial agent of leprosy. They define 16 sub-types of M. leprae and examine their geographical distribution. Reductive evolution and massive pseudogene formation have shaped the 3.31-Mb genome of Mycobacterium leprae, an unculturable obligate pathogen that causes leprosy in humans. The complete genome sequence of M. leprae strain Br4923 from Brazil was obtained by conventional methods (6× coverage), and Illumina resequencing technology was used to obtain the sequences of strains Thai53 (38× coverage) and NHDP63 (46× coverage) from Thailand and the United States, respectively. Whole-genome comparisons with the previously sequenced TN strain from India revealed that the four strains share 99.995% sequence identity and differ only in 215 polymorphic sites, mainly SNPs, and by 5 pseudogenes. Sixteen interrelated SNP subtypes were defined by genotyping both extant and extinct strains of M. leprae from around the world. The 16 SNP subtypes showed a strong geographical association that reflects the migration patterns of early humans and trade routes, with the Silk Road linking Europe to China having contributed to the spread of leprosy.

5 February 2014 in EMBO Molecular Medicine
Verified
Journal Article
Open access
PDF file
VMVadim Makarov
Vadim Makarov
BLBenoit Lechartier
Benoit Lechartier
MZMing Zhang
Ming Zhang
JNJoão Neres
João Neres
ASAstrid M van der Sar
Astrid M van der Sar
SCStewart T Cole
Stewart T Cole
The benzothiazinone lead compound, BTZ043, kills Mycobacterium tuberculosis by inhibiting the essential flavo‐enzyme DprE1, decaprenylphosphoryl‐beta‐D‐ribose 2‐epimerase. Here, we synthesized a new series of piperazine‐containing benzothiazinones (PBTZ) and show that, like BTZ043, the preclinical candidate PBTZ169 binds covalently to DprE1. The crystal structure of the DprE1‐PBTZ169 complex reveals formation of a semimercaptal adduct with Cys387 in the active site and explains the irreversible inactivation of the enzyme. Compared to BTZ043, PBTZ169 has improved potency, safety and efficacy in zebrafish and mouse models of tuberculosis (TB). When combined with other TB drugs, PBTZ169 showed additive activity against M. tuberculosis in vitro except with bedaquiline (BDQ) where synergy was observed. A new regimen comprising PBTZ169, BDQ and pyrazinamide was found to be more efficacious than the standard three drug treatment in a murine model of chronic disease. PBTZ169 is thus an attractive drug candidate to treat TB in humans.

12 July 2013 in Science
Verified
Journal Article
Closed access
PDF file
VSVerena J. Schuenemann
Verena J. Schuenemann
PSPushpendra Singh
Pushpendra Singh
TMThomas A. Mendum
Thomas A. Mendum
BKBen Krause-Kyora
Ben Krause-Kyora
GJGünter Jäger
Günter Jäger
JKJohannes Krause
Johannes Krause
Leprosy: Ancient and Modern: In medieval Europe, leprosy was greatly feared: Sufferers had to wear bells and were shunned and kept isolated from society. Although leprosy largely disappeared from Europe in the 16th century, elsewhere in the world almost a quarter of a million cases are still reported annually, despite the availability of effective drugs. Schuenemann et al. (p. 179 , published online 13 June; see the 14 June News story by Gibbons , p. 1278 ) probed the origins of leprosy bacilli by using a genomic capture-based approach on DNA obtained from skeletal remains from the 10th to 14th centuries. Because the unique mycolic acids of this mycobacterium protect its DNA, for one Danish sample over 100-fold, coverage of the genome was possible. Sequencing suggests a link between the middle-eastern and medieval European strains, which falls in line with social historical expectations that the returning expeditionary forces of antiquity originally spread the pathogen. Subsequently, Europeans took the bacterium westward to the Americas. Overall, ancient and modern strains remain remarkably similar, with no apparent loss of virulence genes, indicating it was most probably improvements in social conditions that led to leprosy's demise in Europe.